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Abstract. Quality by design is an essential part of the modern approach to pharmaceutical quality. There
is much confusion among pharmaceutical scientists in generic drug industry about the appropriate
element and terminology of quality by design. This paper discusses quality by design for generic drugs
and presents a summary of the key terminology. The elements of quality by design are examined and a
consistent nomenclature for quality by design, critical quality attribute, critical process parameter, critical
material attribute, and control strategy is proposed. Agreement on these key concepts will allow
discussion of the application of these concepts to abbreviated new drug applications to progress.
KEY WORDS: control strategy; critical material attributes; critical process parameters; design space;
quality by design.
INTRODUCTION
The Food and Drug Administration (FDA) (1–3) and
pharmaceutical industry (4–6) are talking about quality by
design, and there are many important terms that are used as
part of this discussion. However, industry comments indicate
that there is still much confusion in the generic industry as to
the meaning of quality by design and its associated nomen-
clature. In this paper, we provide a consistent set of
deﬁnitions to provide a clearer understanding of quality by
design for abbreviated new drug applications (ANDAs).
In order to describe quality by design, we must ﬁrst
deﬁne what we mean by quality. In a 2004 paper, Janet
Woodcock (Director for the Center for Drug Evaluation
and Research) deﬁned pharmaceutical quality as a product
that is free of contamination and reproducibly delivers the
therapeutic beneﬁt promised in the label to the consumer
(1). Traditionally, the relationship of product attributes to
product quality has not been well understood, and thus FDA
has ensured quality via tight speciﬁcations based on
observed properties of exhibit or clinical trail batches and
constraining sponsors to use a ﬁxed manufacturing process.
In this approach, speciﬁcations are valued not because they
are related to product quality, but because they are able to
detect differences batch to batch that may potentially have
therapeutic consequences.
FDA’s emphasis on quality by design began with the
recognition that increased testing does not improve product
quality (this has long been recognized in other industries).
The following equation indicates where quality comes from:
Pharmaceutical Quality=f (drug substance, excipients,
manufacturing, packaging).
In order for quality to increase, it must be built into the
product. To do this requires understanding how formulation
and manufacturing process variables inﬂuence product qual-
ity; this is the function f in the equation above.
QUALITY BY DESIGN
We start with the assertion that Quality by Design
(QbD) is a systematic approach to pharmaceutical devel-
opment that begins with predeﬁned objectives and empha-
sizes product and process understanding and process
control, based on sound science and quality risk manage-
ment (7). It means designing and developing formulations
and manufacturing processes to ensure a predeﬁned quality.
Thus, QbD requires an understanding how formulation and
process variables inﬂuence product quality. Relevant docu-
ments from the International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceut-
icals for Human Use (ICH), ICH Q8 (8), Pharmaceutical
Development, along with ICH Q9 (9), Quality Risk Man-
agement, and ICH Q10 (10), Pharmaceutical Quality
Systems, indicate on an abstract level how quality by design
acts to ensure drug product quality. Especially for ANDA
sponsors, who were not actively involved in the ICH
processes, there is a need for more concrete descriptions of
quality by design.
Over the past several years, pharmaceutical scientists
have provided several more speciﬁcd e ﬁnitions of what are
the elements of quality by design (2,4) and a draft of an annex
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generally focused on the development of new drugs. Drawing
on these discussions and some speciﬁca s p e c t so ft h e
development of generic products, a QbD development
process may include (Fig. 1):
& Begin with a target product proﬁle that describes the
use, safety and efﬁcacy of the product
& Deﬁne a target product quality proﬁle that will be
used by formulators and process engineers as a
quantitative surrogate for aspects of clinical safety
and efﬁcacy during product development
& Gather relevant prior knowledge about the drug
substance, potential excipients and process opera-
tions into a knowledge space. Use risk assessment to
prioritize knowledge gaps for further investigation
& Design a formulation and identify the critical material
(quality) attributes of the ﬁnal product that must be
controlled to meet the target product quality proﬁle
& Design a manufacturing process to produce a ﬁnal
product having these critical material attributes.
& Identify the critical process parameters and input
(raw) material attributes that must be controlled to
achieve these critical material attributes of the ﬁnal
product. Use risk assessment to prioritize process
parameters and material attributes for experimental
veriﬁcation. Combine prior knowledge with experi-
ments to establish a design space or other represen-
tation of process understanding.
& Establish a control strategy for the entire process that
may include input material controls, process controls
and monitors, design spaces around individual or
multiple unit operations, and/or ﬁnal product tests.
The control strategy should encompass expected
changesinscaleand can be guided bya riskassessment.
& Continually monitor and update the process to assure
consistent quality
Design of experiments (DOE), risk assessment, and
process analytical technology (PAT) are tools that may be
used in the QbD process when appropriate. They are not
check-box requirements.
The difference between QbD for NDA and ANDA
products is most apparent at the ﬁrst step of the process. For
an NDA, the target product proﬁle is under development
while for the ANDA product the target product proﬁle is well
established by the labeling and clinical studies conducted to
support the approval of the reference product.
DESIGN GOALS
The ﬁrst aspects of QbD are an articulation of the design
goals for the product.
Definition of TPP
FDA published a recent guidance deﬁning a Target
Product Proﬁle (TPP) (11): “The TPP provides a statement of
the overall intent of the drug development program, and
gives information about the drug at a particular time in
development. Usually, the TPP is organized according to the
key sections in the drug labeling and links drug development
activities to speciﬁc concepts intended for inclusion in the
drug labeling.” When ICH Q8 (8) says that pharmaceutical
development should include “...identiﬁcation of those attri-
butes that are critical to the quality of the drug product,
taking into consideration intended usage and route of
administration”, the consideration of the intended usage and
route of administration would be through the TPP.
The TPP is a patient and labeling centered concept, it
can be thought of as the “user interface” of the drug product.
Thus a generic version and its reference product would be
expected to have the same TPP. A generic product may use a
different formulation or design to implement the TPP. The
characteristics and performance tests of a drug product would
depended on the particular implementation and may differ
between a generic and reference product. For a new drug,
changes to the TPP may require new safety or efﬁcacy data,
but changes to product characteristics or performance that
result from a reformulation may not.
ManyaspectsoftheTPPconstrainordeterminetheactions
of formulation and process development scientists. These can
include the route of administration, dosage form and size,
maximum and minimum doses, pharmaceutical elegance (ap-
pearance),andtargetpatientpopulation (pediatric formulations
mayrequirechewabletabletsorasuspension).Commonaspects
of drug product quality are implicitly in the TPP. If the label
statesatabletcontains100mgofactiveingredient,thisisaclaim
relating to the assay and content uniformity. It is the role of a
pharmaceutical scientist to translate the qualitative TPP into
what we deﬁne as the target product quality proﬁle (TPQP) for
further use in a quality by design process.
Definition of TPQP
The target product quality proﬁle (TPQP) (12)i sa
quantitative surrogate for aspects of clinical safety and
efﬁcacy that can be used to design and optimize a formulation
and manufacturing process. International Society of Pharma-
ceutical Engineers (ISPE) Product Quality Lifecycle Imple-
mentation (PQLI) calls this the Pharmaceutical Target
Product Proﬁle (4). It should include quantitative targets for
impurities and stability, release proﬁles (dissolution) and
other product speciﬁc performance requirements. Product
speciﬁc examples include resuspendability for an oral suspen-
sion, adhesion for a transdermal system, and viscosity for a
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Fig. 1. Overview of QbD
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lence to the RLD as part of the TPQP.
The TPQP is not a speciﬁcation because it includes tests
such as bioequivalence or stability that are not carried out in
batch to batch release. The TPQP should only include patient
relevant product performance. For example, if particle size is
critical to the dissolution of a solid oral product, then the
TPQP should include dissolution but not particle size. Particle
size would be a critical material attribute and thus included in
the process description and control strategy. The TPQP
should be performance based and not mechanism based.
Examples of a TPQP can be found in the mock quality
overall summary (QOS) presented on the Ofﬁce of Generic
Drugs website (13,14) although the term TPQP was not clearly
stated in the mock QOS. Another example of a TPQP is
presented in the European Mock P2 (15) that was developed
to facilitate a scientiﬁc and regulatory dialogue between the
Industry Association European Federation of Pharmaceutical
Industries Associations, and Regulatory Authorities on the
presentation of enhanced product and process understanding
in regulatory dossiers. The European Mock P2 uses the
nomenclature Target Product Proﬁle, but their Table I ﬁts
our deﬁnition of a TPQP. They claim that the TPQP is a
deﬁnition of product intended use and a pre-deﬁnition of
quality targets (with respect to clinical relevance, efﬁcacy and
safety) and thus summarizes the quality attributes of the
product required to provide safety and efﬁcacy to the patient.
Definition of CQA
The ISPE PQLI (4)d e ﬁnes critical quality attributes
(CQAs) as physical, chemical, biological or microbiological
properties or characteristics that need to be controlled
(directly or indirectly) to ensure product quality. ICH Q8
(R1) deﬁnes CQAs as physical, chemical, biological or
microbiological properties or characteristics that should be
within an appropriate limit, range, or distribution to ensure
the desired product quality (7). CQA has been used by some
(16) to describe elements of the TPQP (such as dissolution)
while others (17) have used CQA to describe mechanistic
factors (such as particle size and hardness) that determine
product performance. Thus CQA is used to describe both
aspects of product performance and determinants of product
performance.
It was stated that the ICH working deﬁnition of CQA
was: “A CQA is a quality attribute (a physical, chemical,
biological or microbiological property or characteristic) that
must be controlled (directly or indirectly) to ensure the
product meets its intended safety, efﬁcacy, stability and
performance” (18). This CQA deﬁnition implies that the
intended safety, efﬁcacy, stability and performance are not
CQAs. Safety and efﬁcacy clearly fall under the domain of
the TPP. But if stability and performance are not CQA and
not part of the TPP, then what are they? We are thus
compelled to acknowledge that there is an intermediate
category of product performance (or surrogates for quality)
that we have deﬁned as the TPQP.
As shown in Fig. 2, it seems more precise to consider the
TPP, TPQP, and material attributes as separate categories.
The use of CQA can be reserved for cases where there is a
need to refer collectively to the targets of a QbD approach.
CQA is generally assumed to be an attribute of the ﬁnal
product, but it is also possible to indicate a CQA of an
intermediate or a raw material.
All of these categories are sometimes
refered to as
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Fig. 2. An Illustration of How Under QbD the Identiﬁcation of Critical Process Parameters and Critical Material Attributes is Linked to the
TPQP and Finally to TPP that Represents the Clinical Safety And Efﬁcacy
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critical quality attribute, we consider that a set of critical
material attributes (CMAs) that are independent of each
other provide speciﬁc goals with which to evaluate a
manufacturing process. For example a dissolution test may
depend on particle size and hardness. Particle size and
hardness are CMAs which can be directly linked to raw
materials and manufacturing process parameters. Indepen-
dent CMAs are the best way to provide a mechanistic link of
the product quality to the critical process parameters in the
manufacturing process. At the 2005 Drug Information
Association meeting, Reed discussed dissolution in detail
and indicated the greater value of have very speciﬁc CQAs
(19). Others (20) have commented negatively that processing
behavior of materials is usually evaluated in performance
tests (ﬂowability) rather than focusing on fundamental
material properties. Differentiating between CMAs (proper-
ties) and multi-faceted performance tests is part of the
movement away from quality by testing to quality by design.
The evolution of ICH Q8 is also consistent with making a
distinction between CMA and performance tests. The 2004
Q8 draft (21) put CQA and performance tests into the same
pile of physiochemical and biological properties:
The physicochemical and biological properties rel-
evant to the performance or manufacturability of
the drug product should be identiﬁedand discussed.
These could include formulation attributes such as
pH, osmolarity, ionic strength, lipophilicity, dissolu-
tion, redispersion, reconstitution, particle size distri-
bution, particle shape, aggregation, polymorphism,
rheological properties, globule size of emulsions,
biological activity or potency, and/or immunological
activity. Physiological implications of formulation
attributes such as pH should also be addressed.
However, the ﬁnal version of Q8 (8) made clear that this
section was focus on product performance:
The physicochemical and biological properties
relevant to the safety, performance, or manufac-
turability of the drug product should be identiﬁed
and discussed. This includes the physiological
implications of drug substance and formulation
attributes. Studies could include, for example, the
development of a test for respirable fraction of an
inhaled product. Similarly, information supporting
the selection of dissolution vs. disintegration
testing (or other means to ensure drug release)
and the development and suitability of the chosen test
could be provided in this section.
Other examples may help to show the beneﬁt of this
analysis. Consider alcohol induced dose dumping. The TPP
would be the labeling statement (supported by clinical data)
that the product does not dose-dump when taken with
alcohol. A performance test in the TPQP would be an in
vitro dissolution test in alcohol. The CMA would be the
thickness of a tablet coat. Deﬁning the CMAs on this
mechanistic physical property level makes it the best link to
the manufacturing process variables.
CRITICAL PROCESS PARAMETERS
What is a Process Parameter?
There is confusion about what is a process parameter.
Previously, some have deﬁned a critical process parameter
(CPP) as any measurable input (input material attribute or
operating parameter) or output (process state variable or
output material attribute) of a process step that must be
controlled to achieve the desired product quality and process
consistency. In this view, every item in Fig. 3 would be a
process parameter.
We propose that process parameter be understood as
referring to the input operating parameters (mixing speed, ﬂow
rate) and process state variables (temperature, pressure) of a
process or unit operation. Under this deﬁnition, the state of a
process depends on its CPPs and the CMAs of the input
materials. Monitoring and controlling output material attributes
can be a better control strategy than monitoring operating
parameters especially for scale up. For example, a material
attribute, such as moisture content, should have the same target
value in the pilot and commercial processes. An operating
parameter, such as airﬂowrate, wouldbeexpectedto changeas
the process scale changes.
For a given unit operation, there are four categories of
parameters and attributes
& input material attributes
& output material attributes
& input operating parameters
& output process state conditions
What is an Unclassified Process Parameter?
We recognize that there are many material attributes and
process parameters that are important and even essential to
product quality, but it is of little value to deﬁne all parameters
Wet
Granulation
Granulation
State Conditions
Power Consumption
Temperature
Material Attributes
After Granulation
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Granule Size Distribution
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Fig. 3. An Example of Identiﬁcation of Process Parameters and
Material Attributes Prior to Pharmaceutical Development
271 Quality by Design: Concepts for ANDAsas critical. Thus we propose three categories for attributes or
parameters: unclassiﬁed, critical, or non-critical. The critical-
ity of an unclassiﬁed parameter is undetermined or unknown.
Sponsors’ pharmaceutical development studies can provide
the additional data needed to classify an unclassiﬁed param-
eter as critical or non-critical. For a process or dosage form
we expect wide agreement on the set of attributes or
parameters that need classiﬁcation. Prior experience and
standard texts will guide this process. Figure 3 provides an
example identiﬁcation of unclassiﬁed process parameters
(UPP) at the beginning of a development process.
These UPP may later be classiﬁed as critical or non-
critical. For example, in the granulation process, the impeller
speed should clearly be identiﬁed as an unclassiﬁed process
parameter because if impeller speed were zero the process
step would not be successful. However, this does not mean
that impeller speed is always a critical parameter. If develop-
ment studies demonstrated the granulation was not affected
by realistic changes in impeller speed, it would not be
identiﬁed as critical. An application that did not include the
results of pharmaceutical development studies investigating
the criticality of the UPP would have a large number of UPP
remaining in the ﬁnal submission.
What is a Critical Process Parameter?
A parameter is critical when a realistic change in that
parameter can cause the product to fail to meet the TPQP.
Thus, whether a parameter is critical or not depends on how
large of a change one is willing to consider. A simple example
is that an impeller speed of zero will always fail. Thus the ﬁrst
step in classifying parameters is to deﬁne the range of interest
which we call the potential operating space (POS). The POS
is the region between the maximum and minimum value of
interest to the sponsor for each process parameter. The POS
can also be considered as the extent of the sponsor’s quality
system with respect to these parameters. This deﬁnition is at
the discretion of the application that sponsor must balance
the trade-offs in its deﬁnition. The POS deﬁnes the scope of
the application and the sponsor’s quality system so that going
outside of the POS must need an amendment or supplement
to the application. Thus sponsors beneﬁt from deﬁning a large
feasible POS. The cost of a large POS is the need for the
pharmaceutical development (in the form of prior knowledge,
process models or experimental data) to cover the POS and
the increased chance that a parameter will be found critical in
the large POS. The only constraint on the narrowness of the
POS is that the POS must encompass the variability of the
process parameters around their target values.
Our criteria for identifying critical and non-critical param-
eters are that a parameter is non-critical when there is no trend
to failure within the POS and there is no evidence of
interactions within the proven acceptable range (PAR)(see
explanatory footnote on ﬁrst page of article), which is the range
of experimental observations that lead to acceptable quality. A
sponsor has the option of conducting experimental observa-
tions over the entire POS; in this case the POS could be
equivalent to the PAR. Alternatively a sponsor may use prior
knowledge, mechanistic models and trends from the PAR to
draw conclusions about sensitivity over a POS that is larger
than the PAR. If the lack of interaction part of the test cannot
be met, then the parameter remains a UPP. A parameter is
critical when there is an observation of failure or a trend to
failure predicted within the POS. If the interaction between two
parameters is signiﬁcant enough to predict a potential failure in
the POS, then both parameters should be considered as critical.
The most deﬁnitive way to identify critical and non-
critical parameters is by scientiﬁc investigations involving
controlled variations of the parameters. The focus in the
process development report is on the additional studies that
build this knowledge. These studies can be conducted on pilot
or lab scale and do not need to be conducted under current
Good Manufacturing Practice. When the sensitivity of process
parameters is established, this can be used to design
appropriate control strategies.
However, it may not be possible (due to economic and
time constraints) to conduct scientiﬁc investigations on all
UPP. We believe that prior knowledge and experience with
the unit operations can be used to classify some UPP. The
prior knowledge can be used in a formal risk assessment
process to prioritize unclassiﬁed parameters for further
experimental study. This is potentially a challenging issue
for FDA review, if the reviewer does not agree with the risk
assessment used to classify parameters as non-critical, then all
further conclusions may be in doubt because a potential
critical variable was left out of the experimentation that was
used to develop a design space.
Our criteria for identifying critical and non-critical process
parameters are based on the sensitivity of product character-
istics to changes in the process parameters. Other approaches
presented in the literature link the classiﬁcation as critical to
the variability in a process parameter (22,23). The variability of
a process parameter impacts the control strategy that will be
used, but we concur with ISPE PQLI that control of a variable
does not render it non-critical (4). Table I summarizes the
proposed classiﬁcation of process parameters.
Uniqueness of Critical Process Parameters
Because of the broadness of the CPP deﬁnition it is
possible for two investigators to examine the same process
and come to a different set of CPP. The set of CPP is not
unique, but the chosen set must be sufﬁcient to ensure
product quality.
Different sets of CPP can have several origins. One is
that the deﬁnition of operating parameters depends on the
engineering systems installed on a piece of process equip-
ment. For example, one ﬂuid bed dryer may deﬁne the
product temperature as an operating parameter and have an
internal control system (a thermostat) that maintains that
temperature, while another ﬂuid bed dryer may have inlet air
ﬂow rate and inlet air temperature indicated as operating
parameters. The batch record for the ﬁrst unit might indicate
a ﬁxed temperature, while the second unit would have a
design space that indicated the combination of inlet air ﬂow
rate and inlet air temperature that would insure the appro-
priate product temperature.
Another source of differences in the set of CPP comes
from the balance between control of operating parameters
and material attributes. Morris (24) indicates that set of CPP
and CMA (which he refers to as process critical control points
(PCCP)) can affect the scale up process
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of the responses may not scale directly, but the variables
being monitored reﬂect the “state” of the process
& Monitoring material properties makes scaling less equip-
ment dependent (as opposed to only monitoring equip-
ment properties) equipment differences (scale and type)
may have an effect, however, differences in the material
should reﬂect signiﬁcant changes in the PCCPs
CONTROL STRATEGY
A control strategy may include input material controls,
process controls and monitoring, design spaces around
individual or multiple unit operations, and/or ﬁnal product
speciﬁcations used to ensure consistent quality. A control
strategy is what a generic sponsor uses to ensure consistent
quality as they scale up their process from the exhibit batch
presented in the ANDA to commercial production.
Every process has a control strategy right now. Figure 4
shows a simpliﬁed quality assurance diagram under the
current regulatory evaluation system. In this system, product
quality is ensured by ﬁxing the process to produce the active
ingredient, raw material testing, performing the drug product
manufacturing process as described in a ﬁxed batch record,
in-process material testing, and end product testing.
The quality of raw materials including drug substance and
excipients is monitored by testing. If they meet speciﬁcations
or other standards such as USP for drug substance or
excipients, they can be used for manufacturing of the products.
As the drug substance speciﬁcation alone may not be sufﬁcient
to ensure quality, the drug substance manufacturing process is
also tightly controlled. Potentially signiﬁcant changes to the
drug substance manufacturing process will require the drug
product manufacturer to ﬁle supplements with the FDA.
The ﬁnished drug products are tested for quality by
assessing if they meet speciﬁcations. In addition, manufacturers
are usually expected to conduct extensive in process tests, such
as blend uniformity or tablet hardness. Manufacturer are also
not permitted to make changes to the operating parameters (a
large number of UPPs) speciﬁed in the batch record or other
process changes without ﬁlling supplements with the FDA.
This combination of ﬁxed (and thus inﬂexible) manufac-
turing steps and extensive testing is what ensures quality
under the current system. A combination of limited charac-
terization of variability (only three pilot lots for innovator
products and one pilot lot for generic products), a failure of
manufactures to classify process parameters as critical or non-
critical, and cautiousness on the part of regulator leads to
conservative speciﬁcations. Signiﬁcant industry and FDA
resources are being spent debating issues related to accept-
able variability, need for additional testing controls, and
establishment of speciﬁcation acceptance criteria. The rigidity
of the current system is required because manufacturers may
not understand how drug substance, excipients, and manu-
facturing process parameters affect the quality of their
product or they do not share this information with FDA
chemistry, manufacturing and controls (CMC) reviewers.
Thus the FDA CMC reviewers must act conservatively.
A QbD based control strategy is shown in Fig. 5.
Pharmaceutical quality is assured by understanding and
controlling formulation and manufacturing variables to assure
the quality of the ﬁnished product. The end product testing
only conﬁrms the quality of the product. In this example, PAT
Blending
Blend Uniformity
Tapped Density
Discard if fail
Drug Substance
Specification for Drug Substance
Identity, Purity, Particle Size
Based on Exhibit Batch
Variability Not Characterized
Excipients
Specification for Excipient
Meets Compendial Standard
Variability Not Characterized
Batch Record
for Blending
Fixed Order of Addition
Fixed Mixing Speed
Fixed Mixing Time
Fixed Manufacturing
 Process
(maybe in DMF)
Fig. 4. An Example of Control Strategy for Pre-QbD Process
Table I. Classiﬁcation of Process Parameters
Parameter type Deﬁnition Sensitivity
Non-critical process
parameter (non-CPP)
Not critical • No failure in target product quality proﬁle (TPQP)
observed or predicted in the potential operating
space (POS), and
• No interactions with other parameters in the proven
acceptable range (PAR)
Unclassiﬁed process parameter (UPP) Criticality unknown • Not established
• The default in the absence of pharmaceutical
development
Critical process parameter (CPP) Critical (control needed to
ensure quality)
• Failure in target product quality proﬁle (TPQP)
observed or predicted in the potential operating
space (POS), or
• Interactions with other parameters in the proven
acceptable range (PAR)
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ﬁnished product although its use is not required under the
paradigm of the Quality by Design.
Implications of Process Parameter Classification
The classiﬁcation of process parameters as critical or non-
critical is essential to evolve the control strategy toward the
QbD based goal. Full classiﬁcation of all parameters as either
non-criticalorcriticalcanleadtoreducedend-producttesting.It
is the uncertainty about the UPP that leads to extensive testing.
Without development studies, UPP may need to be
constrained at ﬁxed values or narrow ranges (used to produce
acceptable exhibit batches) because they might be critical. The
presence of UPP also leads to inclusion of extensive release
and in-process tests into the control strategies. The goal of
development studies is to move parameter from unclassiﬁed
(criticality unknown) to either non-critical or critical. This
classiﬁcation is an important step toward a ﬂexible manufac-
turing process because unclassiﬁed parameters classiﬁed as
non-critical may be monitored and controlled via monovarient
ranges or as part of a sponsor’s quality system (see Table II).
For non-critical parameters it may be possible to designate a
normal operation range (NOR) up to (or beyond) the proven
acceptable range (PAR) depending on trends and prior
knowledge. The superposition of NOR for non-critical param-
eters would be considered as part of the design space.
The ranges of critical parameters must be constrained to a
multidimensional design space or ﬁxed at values of all
parameters known to be acceptable. Univariate PAR can be
used for critical parameters only when there is evidence that
there are no signiﬁcant interactions between the CPP. However
the establishment of this knowledge about CPPs may render
them lower risk than UPP. A control strategy appropriate to
the known CPP may also have less need for release testing
than one for a process with many UPPs.
Design Space
In the presence of interacting critical process parameters
a design space is one approach to ensure product quality
although it is not a check-box requirement. The current
deﬁnition of design space is “The multidimensional combina-
tion and interaction of input variables (e.g., material attri-
butes) and process parameters that have been demonstrated
to provide assurance of quality.” (8)T h i sd e ﬁnition evolved
from early ICH Q8 drafts where design space was deﬁned as
“the established range of process parameters that has been
demonstrated to provide assurance of quality” (21). The change
emphasizes the multidimensional interaction of input variables
and closely binds the establishment of a design space to a
conduct of a DOE that includes interactions among the input
variables. A design space may be constructed for a single unit
operation, multiple unit operations, or for the entire process.
Submission of a design space to FDA is a pathway
obtaining the ability to operate within that design space without
further regulatory approval. A design space is a way to rep-
resent the process understanding that has been established. The
beneﬁts of having a design space are clear; one challenge to the
effective use of a design space is the cost of establishing it.
In a typical design space approach a sponsor identiﬁes the
unclassiﬁed parameters and then does a DOE on some of the
unclassiﬁed parameters with the other unclassiﬁed parameters
ﬁxed. Thus the end is a regulatory situation where there is some
space for the selected parameters but no ﬂexibility for the other
parameters. This operating parameter based design space is
limited to the equipment used to develop the design space. It
might change on scale up or equipment changes.
In the development of a design space, the key issue to
efﬁciency is demonstrating or establishing that the unclassi-
ﬁed parameters left out of the DOE are truly non-critical
process parameters and are thus by our deﬁnition non-
Blending
Blend Uniformity
Tapped Density
Feedback to ensure quality
Drug Substance
Specification for Drug Substance
Identity, Purity, Particle Size
Based on Relation to Quality
 Variability Understood
Excipients
Specification for Excipient
Meets Compendial Standard
Variability Understood
Batch Record for Blending
Mixing Speed and Time
 adjusted to ensure quality
Flexible Manufacturing Process
 (maybe in separate DMF)
Change without
affecting DP manufacture
Fig. 5. An Example of Control Strategy for QbD Process
Table II. Impact of Classiﬁcation of Process Parameters on Control Strategy
Parameter type Potential control strategies
Non-critical process parameter (non-CPP) • Univarient range in batch record (may extend beyond existing data)
• Under control of sponsors quality system
Unclassiﬁed process parameter (UPP) • Extensive release testing because of uncertainty
• Fix at exhibit batch value or narrow range (to be tested in validation) to
ensure no interactions
Critical process parameter (CPP) • Reduced release testing when all critical process parameters are identiﬁed,
monitored and controlled
• Proven acceptable range if no evidence of multivariate interactions
• Design space to allow multivariate changes
• Feedback control based on measurement of material attributes
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effort should be invested to reduce the number of unclassiﬁed
process parameters. This may involve a screening DOE to
rule out signiﬁcant interactions between process parameters.
When they are non-interacting, univariate ranges for non-
critical parameters are appropriate and can be added to the
design space presentation without additional studies.
It is best to exploit the non-uniqueness of CPPs to deﬁne
the design space in terms of scale independent (dimension-
less) parameters and material attributes. Understanding the
design space in terms of material attributes allows scale up
and equipment changes to be linked to previous experiments.
The scalability of the design space can be evaluated in the
transfer from lab to exhibit batch manufacturing.
Feedback Control and PAT
Application of PAT (25) may be part of a control
strategy. ICH Q8(R) (7) identiﬁes one use of PAT as ensuring
that the process remains within an established design space.
In a passive process, PAT tools provide continuous monitor-
ing of CPP to demonstrate that a process is maintained in the
design space. In process testing of CMA can also be
conducted online or inline with PAT tools. Both of these
applications of PAT are more efﬁcient ways to detect failures.
In a more robust process, PAT can enable active control of
CPP, and if there is variation in the environment or input
materials the operating parameters can be adjusted to keep
the CMA under control to ensure quality.
A PAT system that combines continuous monitoring of
CMA (instead of CPP) can potentially be combined with
feedback control of process parameters to provide an alterna-
tive to design space based control strategies. A problem with
design space is that it can limit ﬂexibility. A design space is
usually a speciﬁed space of process parameters that has been
demonstrated to provide acceptable quality. There may be sets
of process parameters that lead to acceptable quality but were
not explored in the establishment of the design space. Thus,
pursuit of a design space can be movement in the opposite
direction from a ﬂexible and robust manufacturing process.
Direct assessment of product quality via PAT may support
more ﬂexibility and robustness than is represented by the
design space. When CMA can be actively monitored and
feedback control applied to the CPP, then variation in the
environment or input materials can be counteracted by new
values of the CPP (even values outside of a design space that
represents prior experience) to keep the CMA within desired
limits. When direct assessment of product quality by PAT is
established, it may be more valuable to invest pharmaceutical
development resources toward an active control system than
toward documentation of a design space.
CONCLUSIONS
Quality by design is an essential part of the modern
approach to pharmaceutical quality. This paper clariﬁes the
use of QbD for ANDAs including:
& Emphasis on the importance of the Target Product
Quality Proﬁle in articulating a quantitative perfor-
mance target for QbD.
& Identiﬁcation of critical material attributes that
provide a mechanistic link of the product quality to
the manufacturing process.
& Clariﬁcation that critical process parameters are
operating parameters and should be combined with
critical material attributes to describe the relation
between unit operation inputs and outputs.
& Ad e ﬁnition of non-critical, unclassiﬁed, and critical
that provides a way to classify process parameters
and in-process material attributes
& The role of the control strategy as the mechanism for
incremental implementation of QbD elements into
practice
& An efﬁcient path to a design space through the
identiﬁcation of non-interacting process variables
and their exclusion from formal experimental designs.
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